Angela M Davies

Angela M Davies

UNVERIFIED PROFILE

Are you Angela M Davies?   Register this Author

Register author
Angela M Davies

Angela M Davies

Publications by authors named "Angela M Davies"

Are you Angela M Davies?   Register this Author

46Publications

312Reads

24Profile Views

Tumor treating fields: a new frontier in cancer therapy.

Ann N Y Acad Sci 2013 Jul 9;1291:86-95. Epub 2013 May 9.

Novocure, New York, New York 10036, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/nyas.12112DOI Listing
July 2013

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.

J Thorac Oncol 2011 Apr;6(4):774-80

Department of Medical Oncology, University of Colorado Denver, 1665 North Ursula Street, Room 2256, P.O. Box 6510, Mail Stop F-706, Aurora, CO 80045-0508, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31820cf053DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626562PMC
April 2011

Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.

Clin Lung Cancer 2008 ;9 Suppl 3:S129-38

Department of Medical Oncology, Bern University Hospital, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLC.2008.s.019DOI Listing
December 2009

EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.

J Thorac Oncol 2009 Dec;4(12):1466-72

Division of Hematology and Oncology, University of California, Davis Cancer Center, Sacramento, California 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3181bbf239DOI Listing
December 2009

Erlotinib: applications in therapy and current status of research.

Expert Rev Clin Pharmacol 2009 Jan;2(1):15-36

Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan St, 2N35, Portland, OR 97213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17512433.2.1.15DOI Listing
January 2009

Early clinical trial experience with vaccine therapies in non-small-cell lung cancer.

Clin Lung Cancer 2008 Feb;9 Suppl 1:S20-7

Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
February 2008

Bevacizumab: optimal dose, schedule, and duration of therapy.

Clin Lung Cancer 2007 Nov;8(9):522-3

View Article

Download full-text PDF

Source
November 2007

Commentary: Oncologic drugs in patients with organ dysfunction: a summary.

Oncologist 2007 Sep;12(9):1070-83

University of California Davis Cancer Center, 4501 X Street, Sacramento, California 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.12-9-1070DOI Listing
September 2007

Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.

Invest New Drugs 2007 Aug 18;25(4):351-5. Epub 2007 Apr 18.

Davis Cancer Center, University of California, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA.

View Article

Download full-text PDF

Source
http://search.proquest.com/openview/c84b399fa27eafc5746aa1c2
Web Search
http://link.springer.com/10.1007/s10637-007-9045-8
Publisher Site
http://dx.doi.org/10.1007/s10637-007-9045-8DOI Listing
August 2007

Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.

Clin Cancer Res 2007 Aug;13(15 Pt 2):s4583-8

Division of Hematology/Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey, 7th Floor, Suite 7601, Boston, MA 02114, USA. .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0716DOI Listing
August 2007

Incorporating bortezomib into the treatment of lung cancer.

Clin Cancer Res 2007 Aug;13(15 Pt 2):s4647-51

UC Davis Cancer Center, University of California, Sacramento, California 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0334DOI Listing
August 2007

Optimizing targeted therapy in patients with lung cancer with a performance status of 2.

Clin Lung Cancer 2007 Jul;8(7):410-1

View Article

Download full-text PDF

Source
July 2007

Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies.

Clin Lung Cancer 2007 Feb;8 Suppl 2:S61-7

University of California Davis Cancer Center, Sacramento, CA 95817, USA.

View Article

Download full-text PDF

Source
February 2007

Aurora kinase inhibitors: a new class of targeted drugs in cancer.

Clin Lung Cancer 2006 Sep;8(2):93-8

University of California Davis Cancer Center, Sacramento, CA 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLC.2006.n.036DOI Listing
September 2006

The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.

J Thorac Oncol 2006 Jul;1(6):591-601

McMaster University at Hamilton Health Sciences and Juravinski Cancer Centre, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
July 2006

Oral second-line chemotherapy for advanced non-small-cell lung cancer: the bottom line.

J Clin Oncol 2006 Jun 8;24(18):2700-1. Epub 2006 May 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.06.1432DOI Listing
June 2006

Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options.

Clin Lung Cancer 2006 May;7 Suppl 4:S118-25

Division of Hematology and Oncology, University of California Davis Cancer Center, Sacramento, CA 95817, USA.

View Article

Download full-text PDF

Source
May 2006

Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.

Clin Lung Cancer 2006 May;7(6):385-8

Division of Hematology/Oncology, University of California Davis Cancer Center, Sacramento, CA 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLC.2006.n.021DOI Listing
May 2006

Bortezomib-based combinations in the treatment of non-small-cell lung cancer.

Clin Lung Cancer 2005 Oct;7 Suppl 2:S59-63

University of California Davis Cancer Center, Sacramento, 95817, USA.

View Article

Download full-text PDF

Source
October 2005

Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.

Clin Lung Cancer 2005 Oct;7 Suppl 2:S67-71

University of California Davis Cancer Center, Sacramento, 95817, USA.

View Article

Download full-text PDF

Source
October 2005

Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.

Lung Cancer 2005 Aug;49(2):163-70

Division of Surgical Oncology, Suite 3010, University of California, Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2005.01.006DOI Listing
August 2005

Treatment of extensive small cell lung cancer.

Hematol Oncol Clin North Am 2004 Apr;18(2):373-85

University of California-Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2003.12.012DOI Listing
April 2004

Treatment of recurrent small cell lung cancer.

Hematol Oncol Clin North Am 2004 Apr;18(2):387-416

University of California at Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2003.12.010DOI Listing
April 2004

Predictive molecular markers: has the time come for routine use in lung cancer?

J Natl Compr Canc Netw 2004 Mar;2(2):125-31

Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2004.0011DOI Listing
March 2004

Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.

Semin Oncol 2004 Feb;31(1 Suppl 1):40-6

Department of Internal Medicine, University of California Davis School of Medicine, UCD Cancer Center, Sacramento 95817, USA.

View Article

Download full-text PDF

Source
February 2004

Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.

Lung Cancer 2003 Aug;41 Suppl 1:S89-96

Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(03)00149-1DOI Listing
August 2003

Docetaxel in non-small cell lung cancer: a review.

Expert Opin Pharmacother 2003 Apr;4(4):553-65

Division of Hematology-Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, CA 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.4.4.553DOI Listing
April 2003

Antisense oligonucleotides in the treatment of non-small-cell lung cancer.

Clin Lung Cancer 2003 Jan;4 Suppl 2:S68-73

Division of Hematology-Oncology, University of California, Davis, USA.

View Article

Download full-text PDF

Source
January 2003